Dalerba Piero, Dylla Scott J, Park In-Kyung, Liu Rui, Wang Xinhao, Cho Robert W, Hoey Timothy, Gurney Austin, Huang Emina H, Simeone Diane M, Shelton Andrew A, Parmiani Giorgio, Castelli Chiara, Clarke Michael F
Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA.
Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10158-63. doi: 10.1073/pnas.0703478104. Epub 2007 Jun 4.
Recent observations indicate that, in several types of human cancer, only a phenotypic subset of cancer cells within each tumor is capable of initiating tumor growth. This functional subset of cancer cells is operationally defined as the "cancer stem cell" (CSC) subset. Here we developed a CSC model for the study of human colorectal cancer (CRC). Solid CRC tissues, either primary tissues collected from surgical specimens or xenografts established in nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice, were disaggregated into single-cell suspensions and analyzed by flow cytometry. Surface markers that displayed intratumor heterogeneous expression among epithelial cancer cells were selected for cell sorting and tumorigenicity experiments. Individual phenotypic cancer cell subsets were purified, and their tumor-initiating properties were investigated by injection in NOD/SCID mice. Our observations indicate that, in six of six human CRC tested, the ability to engraft in vivo in immunodeficient mice was restricted to a minority subpopulation of epithelial cell adhesion molecule (EpCAM)(high)/CD44+ epithelial cells. Tumors originated from EpCAM(high)/CD44+ cells maintained a differentiated phenotype and reproduced the full morphologic and phenotypic heterogeneity of their parental lesions. Analysis of the surface molecule repertoire of EpCAM(high)/CD44+ cells led to the identification of CD166 as an additional differentially expressed marker, useful for CSC isolation in three of three CRC tested. These results validate the stem cell working model in human CRC and provide a highly robust surface marker profile for CRC stem cell isolation.
最近的观察结果表明,在几种类型的人类癌症中,每个肿瘤内只有一部分具有特定表型的癌细胞能够启动肿瘤生长。这种功能性的癌细胞亚群在操作上被定义为“癌症干细胞”(CSC)亚群。在此,我们开发了一种用于研究人类结直肠癌(CRC)的CSC模型。将实体CRC组织,即从手术标本中采集的原发组织或在非肥胖糖尿病/严重联合免疫缺陷(NOD/SCID)小鼠中建立的异种移植物,解离成单细胞悬液,并通过流式细胞术进行分析。选择在上皮癌细胞中呈现肿瘤内异质性表达的表面标志物进行细胞分选和致瘤性实验。纯化各个表型的癌细胞亚群,并通过注射到NOD/SCID小鼠中来研究它们的肿瘤起始特性。我们的观察结果表明,在测试的6例人类CRC中,有6例在免疫缺陷小鼠体内植入的能力仅限于上皮细胞粘附分子(EpCAM)(高表达)/CD44+上皮细胞的少数亚群。源自EpCAM(高表达)/CD44+细胞的肿瘤保持了分化表型,并重现了其亲代病变的全部形态和表型异质性。对EpCAM(高表达)/CD44+细胞表面分子库的分析导致鉴定出CD166作为另一种差异表达的标志物,在测试的3例CRC中可用于CSC的分离。这些结果验证了人类CRC中的干细胞工作模型,并为CRC干细胞的分离提供了高度可靠的表面标志物谱。